Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

12 trials with published results (26%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

6.4%

3 terminated out of 47 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

19%

9 trials in Phase 3/4

Results Transparency

57%

12 of 21 completed with results

Key Signals

12 with results88% success

Data Visualizations

Phase Distribution

42Total
Not Applicable (8)
Early P 1 (1)
P 1 (3)
P 2 (21)
P 3 (6)
P 4 (3)

Trial Status

Completed21
Recruiting9
Unknown9
Active Not Recruiting3
Terminated3
Not Yet Recruiting1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT06490445Phase 2Active Not RecruitingPrimary

A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06628908Phase 3RecruitingPrimary

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419Phase 3RecruitingPrimary

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860Phase 2RecruitingPrimary

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT07377721Phase 1RecruitingPrimary

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

NCT06812117Active Not RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

NCT07285018Phase 2RecruitingPrimary

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT06696443Phase 3Active Not RecruitingPrimary

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT05895552Phase 2TerminatedPrimary

A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

NCT06203002Phase 2CompletedPrimary

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT07159243Phase 2Not Yet RecruitingPrimary

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

NCT06737861Not ApplicableCompletedPrimary

Buerger Exercises With Whole Body Vibration in Diabetic Peripheral Neuropathy

NCT06361108Phase 1RecruitingPrimary

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06546202CompletedPrimary

Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

NCT00071708Unknown

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

NCT05620576Phase 2CompletedPrimary

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

NCT06490484Phase 2RecruitingPrimary

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

NCT05521737Not ApplicableRecruiting

Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy

NCT06221241Phase 2RecruitingPrimary

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

NCT05177094Phase 2CompletedPrimary

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Scroll to load more

Research Network

Activity Timeline